Protalix BioTherapeutics
PLX
PLX
23 hedge funds and large institutions have $14.8M invested in Protalix BioTherapeutics in 2020 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 1 increasing their positions, 5 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
20% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 10
80% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 5
Holders
23
Holding in Top 10
1
Calls
$378K
Puts
$343K
Top Buyers
| 1 | +$8.97M | |
| 2 | +$202K | |
| 3 | +$183K | |
| 4 |
Capstone Investment Advisors
New York
|
+$80K |
| 5 |
Wolverine Trading
Chicago,
Illinois
|
+$38K |
Top Sellers
| 1 | -$9.42M | |
| 2 | -$751K | |
| 3 | -$605K | |
| 4 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$577K |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$544K |